ArticleDiscover oncology2025
Gender-based differences in survival outcomes of rectal neuroendocrine tumors: a population-based analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeGender-based differences have been shown to affect the prognosis of various tumors, but their role in the survival of rectal neuroendocrine tumors (RNETs) remains unclear. Therefore, we aimed to explore the gender-based differences in the prognosis of RNETs using the Surveillance, Epidemiology, and End Results (SEER) database. MATERIALS AND
methodsRNETs patients from 2000 to 2020 were identified from the SEER database. Propensity score matching (PSM) was used to minimize selection bias. Kaplan-Meier analyses and Cox proportional hazard models were applied to evaluate the impact of clinical characteristics on overall survival (OS) and cancer-specific survival (CSS).
resultsA total of 8247 patients were analyzed, comprising 3990 males and 4257 females. Among the male patients, there was a notably higher proportion of Caucasians and cases of distant metastasis. Before PSM, male patients displayed significantly poorer OS (P < 0.001) and CSS (P < 0.001) compared to female patients. Additionally, they exhibited lower mean OS and CSS rates at 3-, 5-, and 10-year intervals (P < 0.05). After PSM, male patients continued to demonstrate inferior OS (P < 0.001) and CSS (P = 0.031) compared to female patients. Similarly, they maintained lower mean OS and CSS rates across the 3-, 5-, and 10-year intervals (P < 0.05). Multivariate Cox regression identified marital status, age, race, gender, NM stage, surgery, chemotherapy, and tumor size as independent risk factors for OS; marital status, age, gender, TNM stage, surgery, and tumor size for CSS.
conclusionsMale RNET patients exhibit significantly poorer OS and CSS than females, independent of clinical covariates. Gender emerges as a critical prognostic factor in RNETs. Future studies should explore biological mechanisms underlying gender disparities and validate these findings in prospective cohorts to inform gender-stratified clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.